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ARTICLE
Genetics and Genomics
Genome-wide scan of the effect of common nsSNPs on
colorectal cancer survival outcome
Evropi Theodoratou1,2, Susan M Farrington2, Maria Timofeeva2, Farhat VN Din2, Victoria Svinti2, Albert Tenesa3, Tao Liu4,
Annika Lindblom4, Steven Gallinger5, Harry Campbell1,2 and Malcolm G Dunlop2
BACKGROUND: We conducted a genome-wide scan to identify non-synonymous SNPs (nsSNPs) that might influence survival after
a diagnosis of colorectal cancer (CRC).
METHODS: We genotyped 7679 nsSNPs in 1939 Scottish patients from the Scottish Colorectal Cancer Study recruited soon after a
CRC diagnosis and prospectively followed for survival outcomes. All-cause and CRC-specific survival analyses were conducted using
Cox proportional hazard models adjusted for stage, age and sex for all cancer cases, after cancer type stratification and assuming
additive and recessive models of inheritance. For all the SNPs that had a p-value < 0.10 a meta-analysis was performed combining
the results of the discovery set and a replication set of 899 Scottish CRC patients. The p-value threshold of significance was set as at
p < 10−8.
RESULTS: 897 and 894 nsSNPs were associated with all-cause and CRC-specific mortality, respectively, at a p-value level < 0.10 in
the discovery set. Meta-analysis of the results from the discovery and replication sets was performed overall and for cancers of
colon and rectum separately and none of the variants reached a p-value < 10−8.
CONCLUSIONS: This large scale well-powered analysis demonstrates that common nsSNPs are not associated with CRC prognosis
overall.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0117-7
INTRODUCTION
Despite improvements in survival rates from colorectal cancer
(CRC) over the last 25 years, deaths from CRC still account for
~10% of all cancer deaths in the UK (Cancer Research UK, 2014).
Globally, CRC is a significant cause of cancer mortality with
694,000 deaths per annum (8.5% of total).1 Tumour stage at
diagnosis currently provides the most prognostic value, described
by loco-regional and distant spread.2 Alongside age and gender
effects, lifestyle factors such as physical activity and body mass
index influence particular characteristics of the tumour systemic
inflammatory response and impact on cancer survival3,4 However,
there is also evidence of familial concordance for survival in a
number of cancers, including CRC, suggesting that heritable
genetic variation may contribute to prognosis.5 A number of
studies have generated associations between survival outcome
and polymorphic genetic variants6 and in others with combina-
tions of genotype and particular treatments7,8 In a previous study
we examined whether Single nucleotide polymorphism (SNP)s
influencing CRC risk had any effect on survival after diagnosis, and
found that none of ten common genetic variants identified by
genome-wide association studies (GWAS) were associated with
survival from CRC,9 (8q24 (rs6983267),10,11 8q23.3 (rs16892766,
EIF3H),12 10p14 (rs10795668),12 11q23 (rs3802842),13 15q13
(rs4779584),14 18q21 (rs4939827, SMAD7),13,15 14q22.2
(rs4444235, BMP4),16 16q22.1 (rs9929218, CDH1),16 19q13.1
(rs10411210, RHPN2),16 and 20p12.3 (rs961253)16), although more
recent studies have had conflicting and inconsistent results—
minor allele of rs4939827 (SMAD7) associated with reduced overall
and CRC-specific survival;17 five SNPs (rs961253, rs355527,
rs4464148, rs6983267 and rs10505477) associated with survival
of stage III disease;18 rs4444235 significantly associated with
survival in CRC patients;19 patients homozygous for the minor
allele (AA genotype) of rs9929218 had a poorer overall survival
rate;20 studies from East Asians found rs4779584 association with
reduced risk of CRC mortality;21 rs1321311 (CDKN1A) and
rs10411210 (RHPN2) associated with surgically resected CRC,22
and most recently, GG genotype of rs6983267 and the CC
genotype of rs1957636 were significantly associated with poorer
survival outcomes.23 Whilst other studies have utilised GWAS
approaches to identify biomarker of therapeutic response.24
SNPs that alter the encoded amino-acid sequence (non-
synonymous SNPs or nsSNPs), and SNPs mapping within the
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5′ and 3′ untranslated regions of genes (that have a direct
impact on gene expression) are more likely to have a functional
impact, but they are less prevalent in the population.25
Furthermore a large proportion of the SNPs identified as
statistically significantly associated with CRC risk by GWAS (at
GWAS p-value threshold), map to regions of the genome outside
gene boundaries.25 A previous study found no association
between CRC risk and nsSNPs identified by a gene-centric
genome-wide scan.26 Two more studies searched for high-
impact mutations within the exome, a highly enriched subset of
the genome in which disease-causing mutations are most likely to
reside and both studies concluded that recurrent, low-frequency
coding variants account for only a minority of the unexplained
heritability of CRC.27,28
In this study, we interrogated, for the first time, the hypothesis
that nsSNPs may affect CRC prognosis itself. We genotyped a large
prospectively collected population-based cohort of CRC patients
in Scotland (discovery and replication cohorts) for all common
nsSNPs to determine any effect on all-cause or CRC-specific
mortality.
METHODS
Description of study patient population—Scottish cohorts
All CRC patients in the Scottish Colorectal Cancer Study (SOCCS;
discovery cohort SOCCS 1, replication cohort SOCCS 2) were of
Scottish ancestry (defined as parents and all grandparents residing
in Scotland).29 The work received ethical and management
approvals from the MultiCentre Research Ethics committee for
Scotland, 18 Local Research Ethics committees, 18 Caldicott
guardians and 16 NHS Trust management committees, and all
participants provided written informed consent.
Patients were recruited between 1999 and 2006. Recruitment
took place as soon as possible after a confirmed diagnosis of
adenocarcinoma of large bowel epithelium (typically within
3–7 months of diagnosis, median= 150 days, IQR=
89–243 days), in order to minimise survival bias. We recruited
52% of all CRC cases arising in Scotland during the recruitment
period and 98.4% of the recruited cases were finally included in
the SOCCS study (3417 CRC cases). Details of case recruitment
have been described in more detail elsewhere.9,11,15 In brief,
research staff were based in the main surgical centres
throughout Scotland and ascertainment occurred as soon after
admission as possible and clinically appropriate. The main
exclusions were as follows: patient death before ascertainment,
patient too ill to participate, case was a recurrence of CRC or
patient unable to give informed consent due to learning
difficulties or other medical conditions. Patients with a personal
or family history consistent with a dominant polyposis syndrome
or Lynch Syndrome (HNPCC) were excluded from this analysis.
Sequence analysis was undertaken to detect carriers of DNA
mismatch repair gene mutations and the two common MUTYH
mutations were assessed for bi-allelic events.30,31 All such
carriers were also excluded from analysis. In all, genotype data
were available for 3017 CRC cases. Cases were excluded from
the survival analysis for the following reasons: insufficient DNA
for DNA amplification (43 cases), genotyping failure (1 case),
previously unrecognised carriers of another susceptibility allele
(5 cases), gender discrepancies between phenotype database
and genotype (10 cases), date of diagnosis prior to study
initiation date (6 cases), missing data (AJCC stage: 98 cases; date
of diagnosis: 14 cases), duplicates (2 cases). Therefore, in all 2838
cases were included in the survival analysis. Of these cases, 1939
CRC cases constituted the discovery set (SOCCS 1) and the
remaining 899 CRC cases constituted the replication set SOCCS
2. This discovery/replication separation we applied followed the
same Phase I/Phase II separation we used in our previous GWAS
in CRC risk analysis.13
Genotyping, quality control, variant selection
Three aliquots of 10 ml of blood were collected from each case in
one acid citrate dextrose and two sodium ethylenediamin tetra-
acetic acid (EDTA) tubes. DNA was extracted from one of the EDTA
tubes using Nucleon BACC2 kit (GE Healthcare). Median DNA yield
on samples was 327 µg (range: 50–1197 µg). Quality control
procedures included spectrophotometric readings of every
sample (either A260/280 or PicoGreen™), agarose gel electrophor-
esis of uncut and restriction enzyme cut DNA from 2% of samples
and a control PCR on 1% of samples.13
Genotyping for nsSNPs was performed using HumanNS-12
Genotyping BeadChip in 1939 CRC patients.32,33 SNPs were
selected for this panel by screening public databases for all
annotated nsSNPs and it included 11460 nsSNPs.33 After we
excluded SNPs that failed genotyping (n= 3325) and SNPs with a
minor allele frequency (MAF) of <1% (n= 456), 7679 nsSNPs were
genotyped in the discovery set. Of these 7679 nsSNPs, 3888 were
genotyped in the replication set SOCCS 2 (Illumina Infinium
HumanHap300 and HumanHap240S arrays encompassing
~550,000 genome-wide SNPs), a further 3254 were imputed to
1000 Genome Project (phase 1 integrated release 3, March 2012)
with imputation quality info > 0.3 and 537 were not available.
Throughout genotyping was performed using the same quality
control filters as described by us previously.13
Survival analysis
The CRC cases that were included both in the discovery and
replication sets were observed until death or 30th June 2011
(censored date), whichever came first. For 2771 CRC cases
(97.6%) date of diagnosis (incidence date) was provided by the
Scottish Cancer Registry (SCR). All incidence dates were cross-
checked with date of first pathology record and date of
definitive clinical diagnosis, which was taken as start of
treatment (operation, radiotherapy or decision for palliative
therapy). In 67 cases (2.4%), the date of first pathology report
collected at recruitment was used as the cancer incidence date.
Death certificates were provided by the General Register Office
(GRO) for Scotland. There were 810 deaths from the start of
recruitment to the censored date in the discovery set and 345
deaths in the replication cohort SOCCS 2. The cause of death
was determined by a physician examining all death certificates
and there were 610 deaths that were due to CRC (75% of all
deaths) in the discovery set and 317 CRC deaths in the
replication set (92% of all deaths). The protocol devised for
deciding whether the death was related to CRC is presented in
Supplementary Box 1. In all cases, assignment of cause of death
was blinded to the genotype of the deceased subject.
Participant records were linked to SCR and to GRO through
the Community Health Index (CHI), which is a NHS population-
based register of all individuals who are registered with a
general practitioner in Scotland (95% completeness).34
To determine the cancer stage according to the American
Joint Committee on Cancer (AJCC) system the following
procedure was followed. For patients from the South East
Scotland (SCAN) region, computerised tomography scans were
requested and individually checked for evidence of metastasis.
For patients from the West and North of Scotland (WoSCAN and
NoSCAN) regions, respectively, the consultants of individual
patients were contacted by letter requesting staging informa-
tion and clarification of metastasis status for their patients. For
the remaining cases individual general practitioners were
contacted by letter.
All statistical analyses were undertaken using the R software
(version 3.3.3) and the statistical package Intercooled STATA
version 10.0 (Stata Corp, College Station, Texas). T-test Pearson
χ2 test were used to test differences in mean age, sex and AJCC
stage between deceased and survived/ censored cases. A Cox
proportional hazards model adjusted for AJCC stage, age and
nsSNPs and colorectal cancer survival
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sex was used to calculate hazards ratios (HRs) between the SNPs
and death. All-cause and CRC-specific survival analyses were also
run after site stratification (colon versus rectum) and for
different genetic models (additive and recessive). The propor-
tional hazards assumption was checked by fitting a model that
included time-dependent covariates, which were created by
interactions between the predictors (the SNP, age, sex and AJCC)
and survival time. For all the SNPs that had a p-value < 0.10 in
the discovery set, a meta-analysis was performed combining the
results of the discovery and replication set. We planned to type
any SNPs that had a meta-analysis p-value of <10−8 in three
additional cohorts (Scottish replication cohort 2, Canadian
replication cohort and Swedish replication cohort) and to
perform a second meta-analysis. However no SNP passed this
threshold. To assess the credibility of the genetic associations,
we considered the Bayesian False Discovery Probability (BFDP)35
and the False Positive Report Probability (FPRP).36 Both the BFDP
and FPRP are used to assess the noteworthiness of an observed
association. For variants that were found to be statistically
significantly associated with risk of CRC in any of the genetic
models (at p < 10−4), the BFDP was estimated using the R
package “gap”. The BFDP and FPRP thresholds were set up to be
equal to 0.20. We calculated BFDP and FPRP values for three
levels of prior probabilities: at a medium (0.10), low (10–3) and at
a very low prior level (10–4). For FRPR all calculations were done
assuming statistical power to detect an odds ratio of 1.5. Finally,
power calculation was done using the R statistical package
“SurvSNP” implementing the approach as described by Owzar
et al. 2012.37
RESULTS
Supplementary Tables 1 and 2 present summary statistics by
mortality group (all-cause and CRC-specific) of factors influen-
cing survival separately for the discovery and replication sets.
AJCC stage was strongly associated with all-cause and CRC-
specific mortality in the discovery and replication sets. Numbers
of persons at risk, numbers of events and follow-up information
at selected time points for the discovery and replication cohorts
are presented in Supplementary Table 3. The clinical character-
istics of the cases from SCAN, WoSCAN and NoSCAN for the
Scottish cohorts are presented in Supplementary Table 4. MAF
distribution of the 7679 SNPs is shown in Supplementary
Figure 1 (13.4% of variants exhibited a MAF ≤ 0.05; MAF was
0.05–0.20 for 35.7% of variants and MAF > 0.20 for 50.9% of
nsSNPs). We evaluated the inflation of test statistics for the
nsSNP. As expected we observed significant inflation for both
models (recessive and additive). Despite of the significant
inflation, we believe that it is very unlikely it is caused by
population stratification or other bias. The SOCCS study was
previously used in multiple GWAS on CRC risk13,38 and we have
never observed any evidence of population stratification or
inflation in the analysis. However, we do believe that the
observed inflation is caused by results enriched for true
associations, since the array contains only non-synonymous
variants, which could drive the association.
In Table 1 we present the results of the meta-analysis of the
discovery and replication cohorts for those variants that had a p-
value < 10−4. In Supplementary Table 5, we present the effect
estimates separately in the discovery and replication cohort for
each variant presented in Table 1.
The Cox proportional hazards regression analysis of the
discovery set (adjusted for AJCC stage, age and sex) returned
897 nsSNP associations with all-cause mortality under additive
model of inheritance at a p-value level of less than 0.10. Of
these, 846 nsSNPs were either genotyped or imputed in the
replication set SOCCS 2. Meta-analysis of the discovery and
replication sets was performed. None of the SNPs wereT
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statistically significant at p-value < 10−4. Similarly, none of the
nsSNPs were associated with all-cause mortality at a p-value <
10−4 in the analysis restricted to cases with colon and cases with
rectal cancers only.
Similarly, 894 nsSNPs were associated with CRC-specific
mortality under additive model of inheritance at a p-value level
of less than 0.10. Of these, 847 were either genotyped or imputed
in the replication set. Meta-analysis of the discovery and
replication sets was performed. None of the SNPs were statistically
significant at p-value < 10−4 when all cancer cases were com-
bined. However, rs9320001 on chromosome 18 was associated
with CRC-specific mortality (p < 10−4) in patients with rectal cancer
(Table 1).
We further performed analysis assuming a recessive model of
inheritance. 731 nsSNP were associated with all-cause mortality at
a p-value level of less than 0.10. Of these 692 nsSNPs associated
with all-cause mortality at a p ≤ 0.10 were either genotyped or
imputed in the replication set SOCCS 2. None of the variants
reached assigned significance level of p-value < 10−4 in the meta-
analysis of the discovery and replication sets for all cancer cases.
However, rs637186 on chromosome 11 and rs1805016 on
chromosome 16 were associated with all-cause mortality
(p < 10−4) in patients with colon cancer (Table 1).
753 nsSNPs were associated with CRC-specific mortality under
recessive model of inheritance at a p-value level of less than
0.10. Of these, 706 nsSNPs associated with CRC-specific mortality
at a p-value ≤ 0.10 were either genotyped or imputed in the
replication set. Meta-analysis of the discovery and replication
sets was performed and the results of the nsSNPs with a p-value
< 10−4 are presented in Table 1. The variant rs12574508 in
chromosome 11 was associated with CRC-mortality at p-value <
10−4 in the meta-analysis of the discovery and replication sets
for all cancer cases. In addition, rs7258236 on chromosome 19
was associated with CRC mortality (p < 10−4) in patients with
rectal cancer (Table 1).
Supplementary Figure 2 show the relationship between effect
sizes (measured by HR, taking the reciprocal for HRs < 1.0) and
MAF for the 7679 SNPs. We tested for association between stage
at presentation and genotype for each of the SNPs that were
associated with all-cause or CRC-specific mortality at a p-value
level of <10-4 (Supplementary Table 5). Genotypes at all SNPs
showed no relationship with stage at representation. Finally, we
fitted a model including a time-dependent form of the covariates
(AJCC, sex and age) to check the proportional hazards assumption.
The assumption was true for the SNP, age and sex covariates, but
not for the AJCC stage covariate. We therefore re-ran the analysis
stratified by stage after age and sex adjustment. Results for SNPs
that were associated with all-cause and/or CRC-specific mortality
after AJCC stratification at a p-value level of <10-4 are presented in
Supplementary Tables 6 and 7.
To minimise survival bias due to the time gap between day of
diagnosis and recruitment in the study (median time to
recruitment= 150.0), we run all analyses after adjusting for left
truncation by using time to recruitment to create survival objects
in R (Supplementary Table 8). None of the SNPs were statistically
significant at p-value < 10−8.
This study has reasonable power (≥80%) to detect HR of 2.0
for individual SNPs with MAF > 5% in the analysis including all
cancer cases and stratified by colon and rectum (Supplementary
Figure 3). For individual variants exerting lesser effect size (HR >
1.5) the study had ≥80% power for variants (MAF > 10%) in the
analysis that includes all colon and rectal cancers together
(Supplementary Figure 4). We accept that these power estimates
are at the upper range of the estimates, but given that the
genetic architecture of survival outcome for CRC is unknown,
any more complex analysis of power would be highly
speculative. Hence, these seem plausible estimates and empha-
sise that much larger sample sizes would be required, given the
complexity of measured, and unmeasured, variables that impact
on cancer survival outcomes.
DISCUSSION
Main findings
GWAS of tagging SNPs have so far identified around 40 loci that
contribute to the heritable component of CRC risk.39 These genetic
variants are common in populations of European ancestry and
their identification has provided new insights into the aetiology of
CRC.40 An alternative and simple approach is to employ a
genome-wide strategy based on coding variants, as this can
highlight immediately the genes involved in altering disease risk
and progression. In the current study we examined the associa-
tions between a set of 7679 common (MAF ≥ 1%) nsSNPs and all-
cause or CRC-specific mortality in a discovery set of 1939 CRC
cases. We performed a meta-analysis of the discovery and a
replication set of 899 CRC cases (replication set SOCCS 2) for all
the SNPs with a p-value < 0.10. None of the genotyped nsSNPs
had a p-value < 10−8.
Strengths and limitations
The strengths of this study include the systematic and
prospective nature of the collected dataset of CRC cases from
almost all hospitals in Scotland, and the relatively large sample
size of CRC cases compared to other published CRC survival
studies. Cases were recruited as soon as possible after diagnosis
in order to limit survival bias amongst those recruited and
maximise the person years of follow up. We therefore consider
that this systematic study of cancer experience from across a
whole country provides results that are broadly representative
of the general population. In addition, data relevant to the
survival analysis were of high quality, since they were obtained
from the comprehensive Scottish registries GRO and SCR (which
have been shown to have high levels of data quality, validity and
completeness) after linkage of our participants with their
databases using CHI numbers. In addition, considerable effort
was expended to determine and validate the coded AJCC stage
for every case through review of individual pathology, clinical
and imaging records. Finally any positive associations were
explored in four replication cohorts.
A limitation of our study includes the possibility of a relative
under-representation of extremely ill patients at presentation, who
died very soon afterwards, even within the same hospital
admission. It is therefore possible, though unlikely, that external
validity of results may be limited for CRC patients of advanced
AJCC stage or those who present with a complication, such as
bowel obstruction or perforation. Additional co-morbidity might
also have influenced the survival of non-recruited subjects,
independent of cancer stage at presentation. It is unlikely that
treatment differences between hospitals could have affected
survival because CRC clinical management is standardised in
Scotland through the Scottish Intercollegiate Guidelines Network
(SIGN; http://www.sign.ac.uk/). The objective of SIGN is to improve
the quality of health care for patients in Scotland by reducing
variation in practice and outcome. Finally, the HumanNS-12
Genotyping BeadChip array covers only about 30% of the
common non-synonymous variants presented in the UK popula-
tion as compared to the exome array and could offer complete
whole exome coverage of all possible functional variants and
indels. Therefore, population-specific custom arrays as well as
exome and genome sequencing may be a way forward to identify
recurrent rare genetic variation of moderate to large effect sizes.
CONCLUSION
In conclusion, although germline determinants of survival out-
come have enormous potential to shed new light on the
nsSNPs and colorectal cancer survival
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processes of cancer metastasis and the mechanisms leading to
cancer death, we did not identify any nsSNPs that were
convincingly linked to all-cause or CRC mortality. Although, our
study had sufficient power to detect moderate and strong effects
(HR > 2.0) of common nsSNPs, it had limited power to detect very
rare variants or variants of modest effect size. Therefore there is an
urging need in collaborative efforts to increase sample size and
power of genetic association studies on CRC survival.
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